Mirum Pharmaceuticals (NASDAQ:MIRM) Earns "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM - Free Report) in a report issued on Monday, Marketbeat.com reports. The brokerage currently has a $73.00 target price on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at $0.44 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $2.09 EPS.

MIRM has been the topic of a number of other research reports. JMP Securities increased their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Finally, Raymond James reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $60.73.

Mirum Pharmaceuticals Stock Down 0.1%

MIRM traded down $0.05 on Monday, reaching $44.00. The company's stock had a trading volume of 164,520 shares, compared to its average volume of 522,623. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -21.78 and a beta of 0.95. Mirum Pharmaceuticals has a 1 year low of $23.83 and a 1 year high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business's 50 day moving average is $42.95 and its 200 day moving average is $44.59.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $111.59 million during the quarter, compared to the consensus estimate of $98.47 million. During the same quarter in the prior year, the business posted ($0.54) earnings per share. Mirum Pharmaceuticals's revenue for the quarter was up 61.2% on a year-over-year basis. As a group, research analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron bought 1,335 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were purchased at an average price of $45.57 per share, with a total value of $60,835.95. Following the purchase, the director now directly owns 163,643 shares of the company's stock, valued at approximately $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Christopher Peetz sold 27,279 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at $6,129,318.61. The trade was a 16.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 92,764 shares of company stock valued at $4,109,161 in the last quarter. Corporate insiders own 14.36% of the company's stock.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIRM. Barclays PLC increased its position in shares of Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock valued at $9,592,000 after purchasing an additional 10,824 shares during the period. Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $189,000. Secure Asset Management LLC increased its position in shares of Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock valued at $1,651,000 after purchasing an additional 3,406 shares during the period. R Squared Ltd acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $69,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after purchasing an additional 1,003 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.